the MASH thing finally clicked for me and I want to write it down
the MASH thing finally clicked for me and I want to write it down, which sounds obvious until you try to state the evidence for it. Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing. Assumed the weight numbers…
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to
Agreed — and the endpoint definitions are where the actual claim lives.
Agreed that the endpoint definitions matter enormously and almost nobody reads them before quoting a response rate.
a liver endpoint is not a weight endpoint with better marketing
I would not read across from the obesity programmes. Different population, different endpoint, different question.
this board is small because the compound is early
dual GLP-1 and glucagon agonist, and the glucagon arm is the story
phase 2 in liver disease is a different evidence question from weight